Insider Selling: Stoke Therapeutics, Inc. (NASDAQ:STOK) CEO Sells 6,786 Shares of Stock

Stoke Therapeutics, Inc. (NASDAQ:STOK) CEO Edward M. Md Kaye sold 6,786 shares of Stoke Therapeutics stock in a transaction on Monday, December 9th. The stock was sold at an average price of $12.99, for a total value of $88,150.14. Following the completion of the sale, the chief executive officer now directly owns 61,885 shares of the company’s stock, valued at $803,886.15. The trade was a 9.88 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Stoke Therapeutics Stock Down 2.1 %

NASDAQ:STOK traded down $0.28 during mid-day trading on Wednesday, reaching $12.98. The company’s stock had a trading volume of 283,002 shares, compared to its average volume of 748,105. The firm has a market capitalization of $687.55 million, a PE ratio of -6.15 and a beta of 0.95. The stock has a fifty day moving average of $12.46 and a 200-day moving average of $13.68. Stoke Therapeutics, Inc. has a 1 year low of $4.09 and a 1 year high of $17.58.

Stoke Therapeutics (NASDAQ:STOK) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($0.47) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.05. The firm had revenue of $4.89 million during the quarter, compared to analysts’ expectations of $3.46 million. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. On average, analysts expect that Stoke Therapeutics, Inc. will post -2.03 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in STOK. Quest Partners LLC acquired a new position in shares of Stoke Therapeutics during the second quarter valued at about $29,000. Nisa Investment Advisors LLC grew its position in Stoke Therapeutics by 53.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 2,989 shares of the company’s stock worth $40,000 after purchasing an additional 1,038 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in Stoke Therapeutics during the 2nd quarter valued at approximately $123,000. Intech Investment Management LLC acquired a new stake in shares of Stoke Therapeutics during the third quarter worth $160,000. Finally, The Manufacturers Life Insurance Company grew its holdings in shares of Stoke Therapeutics by 16.7% during the second quarter. The Manufacturers Life Insurance Company now owns 13,964 shares of the company’s stock valued at $189,000 after buying an additional 1,994 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on STOK. Leerink Partnrs upgraded Stoke Therapeutics to a “strong-buy” rating in a research note on Friday, October 11th. Leerink Partners initiated coverage on Stoke Therapeutics in a report on Monday, October 14th. They issued an “outperform” rating and a $18.00 target price on the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $22.00 target price on shares of Stoke Therapeutics in a report on Wednesday, November 6th. HC Wainwright reiterated a “buy” rating and set a $35.00 target price on shares of Stoke Therapeutics in a research report on Wednesday, November 6th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Stoke Therapeutics in a research note on Tuesday. One analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $20.83.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.